Liver Diseases  >>  cenicriviroc (TBR-652)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cenicriviroc (TBR-652) / Takeda, AbbVie
CENTAUR, NCT02217475 / 2014-003164-21: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

Checkmark Year 2 analysis of CENTAUR study at EASL 2018 [screenshot]
Apr 2018 - Apr 2018: Year 2 analysis of CENTAUR study at EASL 2018 [screenshot]
Checkmark CENTAUR trial in NASH
Sep 2017 - Sep 2017: CENTAUR trial in NASH
Completed
2
289
US, Europe, RoW
Cenicriviroc, TBR-652, Placebo
Tobira Therapeutics, Inc.
Nonalcoholic Steatohepatitis
06/16
06/17

Download Options